Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB - Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036528

Enrollment

Registered

2019-04-17

Start date

2019-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic mass

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Pancreatic lesions that was detected by imaging examination (e.g. CT, MRI, PET-CT, US, and EUS) and required pathological diagnosis. 2 Age >=20 y 3 Ability to understand and willingness to sign a written statement of informed consent

Exclusion criteria

Exclusion criteria: 1 ECOG PS 4 2 Patients who receive anticoagulant agent. 3 Pregnant or possibly pregnant women. 4 Bleedinfg tendency 5 Patients who are judged inappropriate by medical examine.

Design outcomes

Primary

Measure	Time frame
To evaluate the optimal whitish material length required in the pathological diagnosis in EUS-FNB using a Franseen needle.	—

Secondary

Measure	Time frame
Factor affecting correct diagnosis The relationship between whitish material length and amount of sample.	—

Countries

Japan

Contacts

Public ContactHirotoshi Ishiwatari

Shizuoka Cancer Center Division of Endoscopy

h.ishiwatari@scchr.jp0559895222

Outcome results